Anti-VEGF protein compositions and methods for producing the same
US12054533B2 · kind B2 · utility
0Cited by
83References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2022 |
| Grant date | Aug 6, 2024 |
| Priority date | — |
| Expiry date | Jul 6, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2030/027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.